Annual SG&A
$17.30 M
-$5.21 M-23.13%
31 December 2023
Summary:
Lineage Cell Therapeutics annual selling, general & administrative expenses is currently $17.30 million, with the most recent change of -$5.21 million (-23.13%) on 31 December 2023. During the last 3 years, it has risen by +$1.73 million (+11.12%). LCTX annual SG&A is now -40.61% below its all-time high of $29.13 million, reached on 31 December 2015.LCTX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$4.41 M
+$47.00 K+1.08%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly selling, general & administrative expenses is currently $4.41 million, with the most recent change of +$47.00 thousand (+1.08%) on 30 September 2024. Over the past year, it has increased by +$369.00 thousand (+9.13%). LCTX quarterly SG&A is now -62.85% below its all-time high of $11.87 million, reached on 31 March 2016.LCTX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.57 B
-$20.11 M-1.29%
30 September 2024
Summary:
Lineage Cell Therapeutics TTM selling, general & administrative expenses is currently -$1.57 billion, with the most recent change of -$20.11 million (-1.29%) on 30 September 2024. Over the past year, it has dropped by -$1.59 billion (-9163.49%). LCTX TTM SG&A is now -224700.57% below its all-time high of $36.28 million, reached on 30 June 2016.LCTX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -23.1% | +9.1% | -9163.5% |
| 3 y3 years | +11.1% | -17.1% | -9193.9% |
| 5 y5 years | -30.0% | -4.3% | -6000.7% |
LCTX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -23.1% | +11.1% | -47.9% | +9.1% | -31.4% | at low |
| 5 y | 5 years | -30.0% | +11.1% | -47.9% | +25.4% | -56.5% | at low |
| alltime | all time | -40.6% | +4225.5% | -62.9% | +315.8% | <-9999.0% | at low |
Lineage Cell Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $4.41 M(+1.1%) | $18.06 M(+2.1%) |
| June 2024 | - | $4.36 M(-12.7%) | $17.69 M(+0.6%) |
| Mar 2024 | - | $5.00 M(+16.5%) | $17.57 M(+1.6%) |
| Dec 2023 | $17.30 M(-23.1%) | $4.29 M(+6.1%) | $17.30 M(-0.3%) |
| Sept 2023 | - | $4.04 M(-4.9%) | $17.36 M(-2.1%) |
| June 2023 | - | $4.25 M(-10.1%) | $17.74 M(-5.4%) |
| Mar 2023 | - | $4.72 M(+8.6%) | $18.76 M(-16.6%) |
| Dec 2022 | $22.51 M(+23.6%) | $4.35 M(-1.7%) | $22.51 M(-0.3%) |
| Sept 2022 | - | $4.42 M(-16.1%) | $22.59 M(-3.8%) |
| June 2022 | - | $5.27 M(-37.8%) | $23.48 M(+3.2%) |
| Mar 2022 | - | $8.47 M(+91.4%) | $22.75 M(+24.9%) |
| Dec 2021 | $18.21 M(+17.0%) | $4.42 M(-16.8%) | $18.21 M(+5.2%) |
| Sept 2021 | - | $5.32 M(+17.2%) | $17.30 M(+10.8%) |
| June 2021 | - | $4.54 M(+15.3%) | $15.62 M(+4.2%) |
| Mar 2021 | - | $3.94 M(+11.9%) | $14.99 M(-3.8%) |
| Dec 2020 | $15.57 M(-35.2%) | $3.52 M(-3.1%) | $15.57 M(-6.0%) |
| Sept 2020 | - | $3.63 M(-7.2%) | $16.56 M(-5.6%) |
| June 2020 | - | $3.91 M(-13.5%) | $17.54 M(-11.8%) |
| Mar 2020 | - | $4.52 M(+0.3%) | $19.89 M(-17.2%) |
| Dec 2019 | $24.03 M(-2.8%) | $4.50 M(-2.3%) | $24.03 M(-9.9%) |
| Sept 2019 | - | $4.61 M(-26.4%) | $26.67 M(-6.4%) |
| June 2019 | - | $6.26 M(-27.7%) | $28.48 M(+3.8%) |
| Mar 2019 | - | $8.66 M(+21.3%) | $27.45 M(+10.5%) |
| Dec 2018 | $24.73 M(+24.1%) | $7.14 M(+11.2%) | $24.83 M(+5.7%) |
| Sept 2018 | - | $6.42 M(+22.9%) | $23.50 M(+8.5%) |
| June 2018 | - | $5.23 M(-13.5%) | $21.67 M(+3.9%) |
| Mar 2018 | - | $6.04 M(+4.0%) | $20.86 M(+4.7%) |
| Dec 2017 | $19.92 M(-29.9%) | $5.81 M(+26.7%) | $19.92 M(+2.4%) |
| Sept 2017 | - | $4.59 M(+3.7%) | $19.45 M(+0.1%) |
| June 2017 | - | $4.42 M(-13.3%) | $19.44 M(-10.2%) |
| Mar 2017 | - | $5.10 M(-4.5%) | $21.65 M(-23.8%) |
| Dec 2016 | $28.43 M(-2.4%) | $5.34 M(+16.8%) | $28.43 M(-14.7%) |
| Sept 2016 | - | $4.57 M(-31.1%) | $33.30 M(-8.2%) |
| June 2016 | - | $6.64 M(-44.1%) | $36.28 M(+1.3%) |
| Mar 2016 | - | $11.87 M(+16.1%) | $35.83 M(+23.0%) |
| Dec 2015 | $29.13 M(+65.9%) | $10.22 M(+35.5%) | $29.13 M(+22.9%) |
| Sept 2015 | - | $7.54 M(+22.0%) | $23.70 M(+16.1%) |
| June 2015 | - | $6.19 M(+19.4%) | $20.42 M(+7.1%) |
| Mar 2015 | - | $5.18 M(+8.1%) | $19.07 M(+8.6%) |
| Dec 2014 | $17.56 M(+12.8%) | $4.79 M(+12.4%) | $17.56 M(+3.0%) |
| Sept 2014 | - | $4.26 M(-11.9%) | $17.05 M(-0.0%) |
| June 2014 | - | $4.84 M(+31.9%) | $17.06 M(+7.7%) |
| Mar 2014 | - | $3.67 M(-14.4%) | $15.84 M(+1.6%) |
| Dec 2013 | $15.56 M(+50.1%) | $4.29 M(+0.4%) | $15.59 M(+6.5%) |
| Sept 2013 | - | $4.27 M(+17.8%) | $14.63 M(+16.1%) |
| June 2013 | - | $3.62 M(+6.0%) | $12.60 M(+10.6%) |
| Mar 2013 | - | $3.42 M(+2.7%) | $11.39 M(+10.1%) |
| Dec 2012 | $10.37 M(+11.0%) | $3.33 M(+48.9%) | $10.34 M(+1.8%) |
| Sept 2012 | - | $2.23 M(-7.4%) | $10.17 M(+3.5%) |
| June 2012 | - | $2.41 M(+1.9%) | $9.82 M(+0.1%) |
| Mar 2012 | - | $2.37 M(-24.8%) | $9.81 M(+5.0%) |
| Dec 2011 | $9.34 M(+74.9%) | $3.15 M(+66.8%) | $9.34 M(+23.4%) |
| Sept 2011 | - | $1.89 M(-21.5%) | $7.57 M(+5.9%) |
| June 2011 | - | $2.40 M(+26.4%) | $7.15 M(+13.2%) |
| Mar 2011 | - | $1.90 M(+37.8%) | $6.31 M(+18.1%) |
| Dec 2010 | $5.34 M(+115.7%) | $1.38 M(-5.8%) | $5.34 M(+178.2%) |
| Sept 2010 | - | $1.46 M(-6.5%) | $1.92 M(-37.9%) |
| June 2010 | - | $1.57 M(+67.9%) | $3.09 M(+27.5%) |
| Mar 2010 | - | $933.30 K(-145.7%) | $2.43 M(+11.5%) |
| Dec 2009 | $2.48 M(-4.8%) | -$2.04 M(-177.5%) | $2.18 M(-57.0%) |
| Sept 2009 | - | $2.64 M(+193.0%) | $5.06 M(+57.4%) |
| June 2009 | - | $900.10 K(+31.9%) | $3.22 M(+12.9%) |
| Mar 2009 | - | $682.20 K(-18.9%) | $2.85 M(+9.5%) |
| Dec 2008 | $2.60 M | $840.70 K(+6.1%) | $2.60 M(+21.9%) |
| Sept 2008 | - | $792.30 K(+48.8%) | $2.13 M(+37.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2008 | - | $532.40 K(+22.1%) | $1.56 M(+18.1%) |
| Mar 2008 | - | $435.90 K(+16.9%) | $1.32 M(+1.4%) |
| Dec 2007 | $1.30 M(-12.8%) | $372.80 K(+72.3%) | $1.30 M(+1.6%) |
| Sept 2007 | - | $216.40 K(-26.3%) | $1.28 M(-6.3%) |
| June 2007 | - | $293.80 K(-29.7%) | $1.37 M(-7.4%) |
| Mar 2007 | - | $417.80 K(+18.6%) | $1.47 M(-1.3%) |
| Dec 2006 | $1.49 M(+6.9%) | $352.30 K(+16.7%) | $1.49 M(-0.8%) |
| Sept 2006 | - | $301.90 K(-25.0%) | $1.51 M(+4.1%) |
| June 2006 | - | $402.40 K(-7.9%) | $1.45 M(+4.9%) |
| Mar 2006 | - | $436.90 K(+20.0%) | $1.38 M(-1.2%) |
| Dec 2005 | $1.40 M(-6.0%) | $364.00 K(+49.8%) | $1.40 M(-4.4%) |
| Sept 2005 | - | $243.00 K(-27.4%) | $1.46 M(-2.5%) |
| June 2005 | - | $334.90 K(-26.2%) | $1.50 M(-2.1%) |
| Mar 2005 | - | $454.00 K(+5.9%) | $1.53 M(+3.1%) |
| Dec 2004 | $1.48 M(+17.7%) | $428.90 K(+52.8%) | $1.48 M(+8.2%) |
| Sept 2004 | - | $280.70 K(-23.4%) | $1.37 M(+4.0%) |
| June 2004 | - | $366.30 K(-10.3%) | $1.32 M(-0.9%) |
| Mar 2004 | - | $408.40 K(+28.9%) | $1.33 M(+5.6%) |
| Dec 2003 | $1.26 M(-4.4%) | $316.90 K(+39.4%) | $1.26 M(-15.3%) |
| Sept 2003 | - | $227.40 K(-39.9%) | $1.49 M(+5.4%) |
| June 2003 | - | $378.60 K(+12.1%) | $1.41 M(+6.6%) |
| Mar 2003 | - | $337.80 K(-38.0%) | $1.32 M(+0.5%) |
| Dec 2002 | $1.32 M(-32.8%) | $544.70 K(+259.8%) | $1.32 M(+38.0%) |
| Sept 2002 | - | $151.40 K(-47.9%) | $955.10 K(-37.9%) |
| June 2002 | - | $290.60 K(-12.3%) | $1.54 M(-17.4%) |
| Mar 2002 | - | $331.40 K(+82.4%) | $1.86 M(-5.4%) |
| Dec 2001 | $1.96 M(+10.2%) | $181.70 K(-75.2%) | $1.97 M(-10.7%) |
| Sept 2001 | - | $734.00 K(+19.6%) | $2.20 M(+15.5%) |
| June 2001 | - | $613.50 K(+40.4%) | $1.91 M(+9.5%) |
| Mar 2001 | - | $437.00 K(+4.8%) | $1.74 M(-2.2%) |
| Dec 2000 | $1.78 M(-6.2%) | $417.10 K(-4.9%) | $1.78 M(+1.2%) |
| Sept 2000 | - | $438.70 K(-2.2%) | $1.76 M(+2.2%) |
| June 2000 | - | $448.70 K(-5.6%) | $1.72 M(-8.1%) |
| Mar 2000 | - | $475.50 K(+19.9%) | $1.87 M(-1.3%) |
| Dec 1999 | $1.90 M(+171.0%) | $396.70 K(-0.8%) | $1.90 M(+26.4%) |
| Sept 1999 | - | $400.00 K(-33.3%) | $1.50 M(0.0%) |
| June 1999 | - | $600.00 K(+20.0%) | $1.50 M(+7.1%) |
| Mar 1999 | - | $500.00 K(+25.0%) | $1.40 M(-17.6%) |
| Dec 1998 | $700.00 K(-61.1%) | - | - |
| Sept 1998 | - | $400.00 K(-20.0%) | $1.70 M(-5.6%) |
| June 1998 | - | $500.00 K(+25.0%) | $1.80 M(+5.9%) |
| June 1998 | $1.80 M(+50.0%) | - | - |
| Mar 1998 | - | $400.00 K(0.0%) | $1.70 M(+13.3%) |
| Dec 1997 | - | $400.00 K(-20.0%) | $1.50 M(+7.1%) |
| Sept 1997 | - | $500.00 K(+25.0%) | $1.40 M(+16.7%) |
| June 1997 | $1.20 M(-42.9%) | $400.00 K(+100.0%) | $1.20 M(+50.0%) |
| Mar 1997 | - | $200.00 K(-33.3%) | $800.00 K(+33.3%) |
| Dec 1996 | - | $300.00 K(0.0%) | $600.00 K(+100.0%) |
| Sept 1996 | - | $300.00 K(+200.0%) | $300.00 K(-57.1%) |
| June 1996 | $2.10 M(+162.5%) | - | - |
| Sept 1995 | - | $100.00 K(-50.0%) | $700.00 K(-12.5%) |
| June 1995 | $800.00 K(-11.1%) | $200.00 K(0.0%) | $800.00 K(-11.1%) |
| Mar 1995 | - | $200.00 K(0.0%) | $900.00 K(0.0%) |
| Dec 1994 | - | $200.00 K(0.0%) | $900.00 K(0.0%) |
| Sept 1994 | - | $200.00 K(-33.3%) | $900.00 K(0.0%) |
| June 1994 | $900.00 K(+12.5%) | $300.00 K(+50.0%) | $900.00 K(+12.5%) |
| Mar 1994 | - | $200.00 K(0.0%) | $800.00 K(0.0%) |
| Dec 1993 | - | $200.00 K(0.0%) | $800.00 K(0.0%) |
| Sept 1993 | - | $200.00 K(0.0%) | $800.00 K(0.0%) |
| June 1993 | $800.00 K(+100.0%) | $200.00 K(0.0%) | $800.00 K(0.0%) |
| Mar 1993 | - | $200.00 K(0.0%) | $800.00 K(+14.3%) |
| Dec 1992 | - | $200.00 K(0.0%) | $700.00 K(+40.0%) |
| Sept 1992 | - | $200.00 K(0.0%) | $500.00 K(+66.7%) |
| June 1992 | $400.00 K | $200.00 K(+100.0%) | $300.00 K(+200.0%) |
| Mar 1992 | - | $100.00 K | $100.00 K |
FAQ
- What is Lineage Cell Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual SG&A year-on-year change?
- What is Lineage Cell Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly SG&A year-on-year change?
- What is Lineage Cell Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics TTM SG&A year-on-year change?
What is Lineage Cell Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of LCTX is $17.30 M
What is the all time high annual SG&A for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual selling, general & administrative expenses is $29.13 M
What is Lineage Cell Therapeutics annual SG&A year-on-year change?
Over the past year, LCTX annual selling, general & administrative expenses has changed by -$5.21 M (-23.13%)
What is Lineage Cell Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of LCTX is $4.41 M
What is the all time high quarterly SG&A for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly selling, general & administrative expenses is $11.87 M
What is Lineage Cell Therapeutics quarterly SG&A year-on-year change?
Over the past year, LCTX quarterly selling, general & administrative expenses has changed by +$369.00 K (+9.13%)
What is Lineage Cell Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of LCTX is -$1.57 B
What is the all time high TTM SG&A for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high TTM selling, general & administrative expenses is $36.28 M
What is Lineage Cell Therapeutics TTM SG&A year-on-year change?
Over the past year, LCTX TTM selling, general & administrative expenses has changed by -$1.59 B (-9163.49%)